脂联素与内脂素在不同糖耐量妊娠个体中的变化及对β细胞分泌功能的影响
|
摘要
目的通过对不同糖耐量状态妊娠个体中脂联素(ADPN)和内脂素的测定和相关因素研究,探讨在不同糖耐量状态妊娠个体的ADPN和内脂素水平变化以及ADPN与内脂素在妊娠糖尿病(GDM)中对于胰岛β细胞分泌功能的影响和在GDM发病中的可能机制。方法根据GDM的诊断标准和不同糖耐量进行分组:分为GDM组(33例)、妊娠糖耐量异常(GIGT)组(33例)和正常妊娠(NGT)组(30例)。检测血清ADPN(ELISA法)、内脂素(ELISA法),同时测定空腹和餐后血糖、HbAlc、血脂水平、空腹和餐后胰岛素、空腹和餐后C肽、内分泌激素(甲状腺激素、孕酮、雌二醇、血PRL)等指标,比较各组间的差异并进行相关性分析。结果1)不同糖耐量状态妊娠个体的总体脂和股部皮下脂肪面积(FA)无差异;随着糖耐量损伤程度的加重,腹部内脏脂肪面积(VA)和腹部皮下脂肪面积(SA)明显增加,P<0.05。2)GDM、GIGT组的空腹和餐后胰岛素、C肽明显增高,且GDM餐后胰岛素和C肽明显高于GIGT,P<0.05。3)糖耐量异常妊娠个体孕激素和泌乳素分泌量明显增加,而游离甲状腺素无明显升高。GDM游离三碘甲状原氨酸高于GIGT患者。4)与NGT组相比,GDM、GIGT组血清ADPN明显下降,P<0.05;GDM组血清ADPN高于GIGT组,P<0.05。5)GDM的空腹和餐后血清内脂素明显高于GIGT和NGT,而GIGT与NGT无差异;各组的空腹与餐后血清内脂素无统计学差异。6)ADPN随孕周的进展无变化,而血清内脂素在孕中期无变化,但在孕晚期明显增高。7)多元逐步回归分析显示:BMI、VA、SA、2hPG、FINS、餐后2小时胰岛素、空腹C肽、餐后C肽、HOMA-IR等与ADPN水平密切相关;而BMI、FPG、1hPG、2hPG、3hPG、FINS、空腹C肽、VA、SA等与血清内脂素密切相关。8)ADPN与HbA1c、FPG、1hPG、2hPG、3hPG呈正相关,与BMI、年龄、HDL、VA呈负相关;血清内脂素与FPG、1hPG、2hPG、3hPG、FINS、空腹C肽、HOMA-IR、VA、SA呈现正相关,与ISI呈负相关。结论糖耐量损伤的妊娠个体不仅存在由于胰岛素抵抗所致的胰岛素大量释放,还存在胰岛素释放延迟。血清内脂素在妊娠进展的过程中可以随着孕周的变化而变化。ADPN的分泌增加可以促进胰岛β细胞分泌胰岛素,而血清内脂素受到血糖的刺激,可以增加分泌,发挥其类胰岛素的作用,同时内脂素也可以影响胰岛素的分泌,共同起到降低血糖的作用。
Objective: To investigate the serum adiponectin; visfatin and related factors in pregnancy patients with different glucose tolerance, discussion on the changes of adiponectin and visfatin levels in pregnancy patients with different glucose tolerance and the effect the secretary function of Beta cell, analysis possible mechanisms in GDM.
Methods: According to the diagnostic criteria of GDM and impaired glucose tolerance, the patients were divided into three groups: gestational diabetes mellitus(GDM) group: (33 cases), gestational impaired glucose tolerance (GIGT) group: (33 cases) and normal pregnancy (NGT) group: (30 cases). Serum adiponectin and visfatin was measured by ELISA. At the same time, measured fasting blood glucose and postprandial, HbAlc, blood lipid levels, fasting and postprandial insulin, fasting and postprandial C-peptide, endocrine hormones and so on, compare the differences between the groups and correlation analysis.
Results: (1) The overall fat and femoral subcutaneous fat area (FA) were no differences in three groups; with the tolerance level of injury increased abdominal visceral fat area (VA) and abdominal subcutaneous fat area (SA) increased significantly. (2) The fasting and postprandial insulin and C peptide increased significantly in GDM and GIGT groups, the postprandial insulin and C peptide in GDM group were significantly higher than GIGT group. (3) Progesterone and prolactin secretion increased, and free thyroxine had no significant rise in Pregnancy patients with impaired glucose tolerance, free Triiodothyronine in GDM group was higher than GIGT group. (4) The level of serum adiponectin was lower in GDM and GIGT groups than NGT group, the serum adiponectin in GDM was higher than GIGT group. (5) The level of serum fasting and postprandial visfatin in GDM were higher than GIGT and NGT. The fasting and postprandial visfatin have no significant differences in every group. (6) With the progress of gestational age, there is no change in the level of serum ADPN; Serum visfatin has no change in the second trimester, but increased significantly in the third trimester of pregnancy. (7) Multiple regression analysis showed that: BMI, VA, SA, 2hPG, Fasting and postprandial insulin and C-peptide, HOMA-IR are closely related to the level of ADPN; and BMI, FPG, 1hPG, 2hPG, 3hPG, FINS, fasting C-peptide, VA, SA are closely related to the level of visfatin. (8) Correlation analysis indicated serum adiponectin was positively associated with HbA1c, FPG, 1hPG, 2hPG and 3hPG,negatively associated with BMI, age, HDL and VA; serum visfatin was positively associated with FPG, 1hPG, 2hPG, 3hPG, FINS, fasting C-peptide, HOMA-IR, VA and SA, negatively associated with ISI.
Conclusions: Damage in pregnancy patients with impaired glucose tolerance is not only due to presence of the large number of insulin release caused by insulin resistance, there are still delays in the release of insulin. With the change of gestational age, serum visfatin and ADPN levels are also changing, and their secretion are increasing by the stimulation of high blood sugar.ADPN and visfatin may play an important role in Insulin-like effect and the promotion of insulin-secreting isletβcells.
Objective: To investigate the serum adiponectin; visfatin and related factors in pregnancy patients with different glucose tolerance, discussion on the changes of adiponectin and visfatin levels in pregnancy patients with different glucose tolerance and the effect the secretary function of Beta cell, analysis possible mechanisms in GDM.
Methods: According to the diagnostic criteria of GDM and impaired glucose tolerance, the patients were divided into three groups: gestational diabetes mellitus(GDM) group: (33 cases), gestational impaired glucose tolerance (GIGT) group: (33 cases) and normal pregnancy (NGT) group: (30 cases). Serum adiponectin and visfatin was measured by ELISA. At the same time, measured fasting blood glucose and postprandial, HbAlc, blood lipid levels, fasting and postprandial insulin, fasting and postprandial C-peptide, endocrine hormones and so on, compare the differences between the groups and correlation analysis.
Results: (1) The overall fat and femoral subcutaneous fat area (FA) were no differences in three groups; with the tolerance level of injury increased abdominal visceral fat area (VA) and abdominal subcutaneous fat area (SA) increased significantly. (2) The fasting and postprandial insulin and C peptide increased significantly in GDM and GIGT groups, the postprandial insulin and C peptide in GDM group were significantly higher than GIGT group. (3) Progesterone and prolactin secretion increased, and free thyroxine had no significant rise in Pregnancy patients with impaired glucose tolerance, free Triiodothyronine in GDM group was higher than GIGT group. (4) The level of serum adiponectin was lower in GDM and GIGT groups than NGT group, the serum adiponectin in GDM was higher than GIGT group. (5) The level of serum fasting and postprandial visfatin in GDM were higher than GIGT and NGT. The fasting and postprandial visfatin have no significant differences in every group. (6) With the progress of gestational age, there is no change in the level of serum ADPN; Serum visfatin has no change in the second trimester, but increased significantly in the third trimester of pregnancy. (7) Multiple regression analysis showed that: BMI, VA, SA, 2hPG, Fasting and postprandial insulin and C-peptide, HOMA-IR are closely related to the level of ADPN; and BMI, FPG, 1hPG, 2hPG, 3hPG, FINS, fasting C-peptide, VA, SA are closely related to the level of visfatin. (8) Correlation analysis indicated serum adiponectin was positively associated with HbA1c, FPG, 1hPG, 2hPG and 3hPG,negatively associated with BMI, age, HDL and VA; serum visfatin was positively associated with FPG, 1hPG, 2hPG, 3hPG, FINS, fasting C-peptide, HOMA-IR, VA and SA, negatively associated with ISI.
Conclusions: Damage in pregnancy patients with impaired glucose tolerance is not only due to presence of the large number of insulin release caused by insulin resistance, there are still delays in the release of insulin. With the change of gestational age, serum visfatin and ADPN levels are also changing, and their secretion are increasing by the stimulation of high blood sugar.ADPN and visfatin may play an important role in Insulin-like effect and the promotion of insulin-secreting isletβcells.
引文
[1] Cunningham FG, Gant NF, Leveno KJ, et al. Diabetes. Williams Obsterrics. 21th ed.北京:科学技术出版社, 2002, 1360-1377.
[2] Hollander MH, Paarlberg KM, Huisjes AJ. Gestational diabetes: a review of the current literature and guidelines. Obstet Gynecol Surv. 2007 Feb; 62(2): 125-36.
[3] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagonsis and classification of diabetes mellitus. Diabetes Care, 2003, 26 Suppl 1: S5-20.
[4] Wijeyaratne CN, Ginige S, Arasalingam A, et al. Screening for gestational diabetes mellitus: the Sri Lankan experience. Ceylon Med J. 2006 Jun; 51(2): 53-8.
[5] Kim C, Newton KM,Knopp RH.Gestational diabetes mellitus. Diabetesand incidence of type 2 diabetes: a systematic review.Diabetes Care, 2002, 25: 1862-1868.
[6] American Diabetes Association:Gestational diabetes mellitus.Diabetes Care, 2004, 27 Suppl 1: s88-90.
[7] Case J, Willoughby D, Haley-Zitlin V, et al. Preventing type 2 diabetes after gestational diabetes. Diabetes Educ. 2006 Nov-Dec; 32(6): 877-86.
[8] Kieffer EC, Tabaei BP, Carman WJ, et al. The influence of maternal weight and glucose tolerance on infant birthweight in Latino mother-infant pairs. Am J Public Health. 2006 Dec; 96(12): 2201-2208.
[9] Freire CM, Nunes Mdo C, Barbosa MM, et al. Gestational diabetes: a condition of early diastolic abnormalities in young women. J Am Soc Echocardiogr. 2006 Oct; 19(10): 1251-6.
[10] Shuldiner AR,Yang R,Gong DW. Resistin, obesity and insulin resistance-theemerging role of the adipocyte as an endocrine or gan. N Engl J Med, 2001, 345(18): 1345.
[11] Hotamisligil GS, Shargill NS,Spiegelman BM, et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.Science. 1993 Jan 1; 259(5091): 87-91.
[12] Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased visfatin concentrations in women with gestational diabetes mellitus [J].Clin Sci (Lond), 2006, 110(5): 605-609.
[13] Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001 Aug; 7(8): 941-6.
[14] Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001 Aug; 7(8): 947-53.
[15] Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun; 89(6): 2548-56.
[16] Kadowaki T, Yamauchi T. Adiponectin and adiponectin eceptors. Endocr Rev. 2005 May; 26(3): 439-51.
[17] Kadowaki T, Hara K, Yamauchi K, et al. Molecularmechanismof insulin resistance and obesity [J]. Exp Biol Med, 2003, 228(10): 1111-1117.
[18] Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat thatmimics the effects of insulin [J]. Science, 2005, 307(5708): 426-430.
[19] American Diabetes Assccietion. Gestational diabetes mellitus. Diabetes care, 2002; 25: s94-96.
[20] American Diabetes Association:Gestational diabetes mellitus. Diabetes Care, 2004, 27 Suppl 1: s88-90.
[21] Boland E, Monsod T, Delucia M, et al. Limitations of conventional methodsof self-monitoring of blood glucose: lessons learned from 3 day of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care, 2001, 24: 1858-1862.
[22] Yamashita H, Jianhua S, Friedman JE. Physiologic and moleculae altera tions incarbohydrate metabolism during pregnancy and gestational. Diabetes Mellitus. J. Clin. Obst. Gyn. 2000, 43: 87-98.
[23] Okereke NC, Huston-Presley L, Amini SB,Kalhan S, Catalano PM.Longitudinal changes in energy expenditure and body composition in obese women with nomal and impaired glucose tolerance. Am J Physiol Endocrinol Metad. 2004; 287(3): E472-279.
[24] Connolly CC, Aglione, Smith MS, Lacy DB, Moore MC.Insulin action during late pregnancy in the conscious dog? Am J Physiol Endocrinol Metad. 2004; 286(6): E909-915.
[25] Mulford MI, Jovanonic-peterson CM. Alternative therapies for the management of gestational diabetes. Clin Perintol, 1993; 20: 619-634.
[26] Fadl H, Ostlund I, Nilsson K, et al. Fasting capillary glucose as a screening test for gestational diabetes mellitus. BJOG. 2006 Sep; 113(9): 1067-71.
[27] Akbay E, Tira MB, Yetkin, et al. Insulin secretion and insulin sensitivity in normal pregnancy and gestational diabetes mellitus. Gynecol Endocrinol, 2003, 17: 137-142.
[28] Smirnakis KV, Martinez A, Blatman KH, et al. Early pregnancy insulin resistance and subsequent gestational dibetes mellitus. Diabetes Care, 2005, 28: 1207-1208.
[29] Buchanan TA, Xiang A, Kjos SL, et al. Gestational diabetes:antepartum characteristics that predict postpartum glucose intolerance and type 2 diabetes in Latino women. Diabetes, 1998, 47: 1302-1310.
[30] Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational diabetes mellitusand its association with Type 2 diabetes. Diabet Med, 2004, 21(2): 103-113.
[31] Maeda K, Okubo K, Shimomura I, et al. c-DNA cloning and expression of a noveladipose specific collagen-like factor, apMI (Adipose Most abundant Gene transcript1). Biochem Biophys Res Commun, 1996. 221: 286-289.
[32] Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 2001, 7: 941-946.
[33] Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substance. Ann N Y Acad Sci, 1999, 892: 146-154.
[34] Yokota T, Oritani K, Takahashi I, et al, Adiponectin, a new member of the family of soluble defense collages, negatively regulates the growth of mywlomonocytic progenitors and the functions of macrophages. Blood, 2000, 96: 1723-1732.
[35] Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 1999, 100: 2473-2476.
[36] Ranheim T, Haugen F, Staff A, et al, Adiponectin is reduced in gestational diabetes mellitus in normal weight women, Acta Obstet Gynecol Scand, 2004, 83(4): 341-347.
[37] Ranheim T, Haugen F, Staff AC, et al. Adiponectin is reduced in gestational diabetes mellitus in normal weight woman. Acta Obstet Gynecol Scand, 2004, 83(4): 341-347.
[38] Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased visfatin concentrations in women with gestational diabetes mellitus [J]. Clin Sci (Lond), 2006, 110(5): 605-609.
[39]陈蕾,项坤三,贾伟平等.血清脂联素浓度与体脂分布及葡萄糖钳夹试验中胰岛素敏感性的关系.中华医学杂志. 2005, 85(21): 1456-1459.
[40] Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fatdepot- specificm RNA expression in humans [J]. Diabetes, 2005, 54(10): 2911-2916.
[41] Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 [J]. Nat Med, 2002, 8(7): 731-737.
[42] Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes; close associationwith insulin resistance and hyperinsulinemia [J]. J Clin Endocrinol Metab, 2001, 86(5): 1930-1935.
[43] Winzell MS, Nogueiras R, Dieguez C, et al. Dual action of adiponectin on insulin secretion in insulin-resistant mice [J]. Biochem Biophys Res Commun,2004, 321(1): 154-160.
[44] Furuta M, Tamai M, HanabusaT, et al. Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients [J]. Diabetes Res Clin Pract, 2006, 72(3): 302-307.
[45] Sethi JK,Vidal-PuigA.Visfatin: themissing link between intra-abdominal obesity and diabetes? [J]. Trends MolMed, 2005, 11(8): 344-347.
[46] Kralisch S, Klein J, LossnerU, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes [J]. J Endocrino, l, 2005, 185(3): R1-R8.
[47] Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fatdepot- specificm RNA expression in humans [J]. Diabetes, 2005, 54(10): 2911-2916.
[48] Haider DG, Schaller G, Kapiotis S, et al. The release of the adipocytokine visfatin is regulated by glucose and insulin [J]. Diabetologia, 2006, 49(8): 1909-1914.
[49] Filippatos TD, Derdemezis CS, Kiortsis DN, et al. Increased plasma levelsof visfatin/ pre-B cell colony-enhancing factor in obese and over weight patients with metabolic syndrome [J]. J Endocrinol Invest, 2007, 30(4): 323-326.
[50]刘蓉,朱剑,王茜,等.不同糖耐量人群及糖尿病患者血浆内脂素与血糖及胰岛功能的关系研究[J].中国实用内科杂志, 2007, 27(16): 1278-1281.
[1] Kim C, Newton KM, Knopp RH. Gestational diabetes mellitus. Diabetesand incidence of type 2 diabetes: a systematic review. Diabetes Care, 2002, 25: 1862-1868.
[2] American Diabetes Association: Gestational diabetes mellitus.Diabetes Care, 2004, 27 Suppl 1: s88-90.
[3] Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat thatmimics the effects of insulin [J]. Science, 2005, 307(5708): 426-430.
[4] Shuldiner AR,Yang R, Gong DW. Resistin, obesity and insulin resistance-the emerging role of the adipocyte as an endocrine organ.N Engl J Med, 2001, 345(18):1345-6.
[5] Hotamisligil GS, Shargill NS, Spiegelman BM, et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 1993, 259 (5091): 87-91.
[6] Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature, 1994, 372(6505): 425-32.
[7] Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature, 2001, 18; 409 (6818): 307-12.
[8] Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.Nature, 2005, Jul 21; 436 (7049): 356-62.
[9] Shulman GI. Cellular mechanisms of insulin resistance.J Clin Invest, 2000 Jul; 106(2): 171-6.
[10] Friedman JM. Obesity in the new millennium. Nature, 2000 Apr 6; 404(6778): 632-4.
[11] Hotamisligil GS.The role of TNF alpha and TNF receptors in obesity and insulin resistance. J Intern Med,1999, Jun; 245(6): 621-5.
[12] Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol, 2006, Oct; 6(10): 772-83.
[13] Moschos S, Chan J L, Mantzoros C S. Leptin and reproduction: a review. Fertil Steril, 2002; 77( 3): 433-444.
[14] Straczkowski M, Kowalska I, Dzienis-Straczkowska S, et al. Changes in tumor necrosis factor-αsystem and insulin sensitivity during an exercise training program in obese woman with normal and impaired goucose tolerance. Eur J Endocrinol, 2001, 45(3): 273-280.
[15] Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem, 1995, Nov 10; 270(45): 26746-9.
[16] Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem,1996, May 3; 271(18): 10697-703.
[17] Maeda K, Okubo K, Shimomura I, et al. c-DNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun, 1996, Apr 16; 221(2): 286-9.
[18] Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo), 1996, Oct; 120(4): 803-12.
[19] Crouch E, Persson A, Chang D, et al. Molecular structure of pulmonary surfactant protein D (SP-D). J Biol Chem, 1994, Jun 24; 269 (25): 17311-9.
[20] McCormack FX, Pattanajitvilai S, Stewart J, et al. The Cys6 intermolecular disulfide bond and the collagen-like region of rat SP-A play critical roles in interactions with alveolar type II cells and surfactant lipids. J Biol Chem, 1997, Oct 31; 272(44): 27971-9.
[21] Wong GW, Wang J, Hug C, et al. A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci U S A, 2004, Jul 13; 101(28): 10302-7.
[22] Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens,negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 2000, Sep 1; 96(5):1723-32.
[23] Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol, 1998, Mar 12; 8(6): 335-8.
[24] Schaffler A, Barth N, Palitzsch KD, et al. Mutation analysis of the human adipocyte- specific apM-1 gene. Eur J Clin Invest, 2000, Oct; 30(10): 879-87.
[25] Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord, 2000, Jul; 24(7): 861-8
[26] Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes, 2002, Sep; 51(9): 2734-41.
[27] Xu A, Chan KW, Hoo RL, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem, 2005, May 6; 280(18): 18073-80.
[28] Nagasawa A, Fukui K, Funahashi T, et al. Effects of soy protein diet on the expression of adipose genes and plasma adiponectin. Horm Metab Res, 2002, Nov-Dec; 34(11-12): 635-9.
[29] Flachs P, Mohamed-Ali V, Horakova O, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia, 2006 Feb; 49(2): 394-7.
[30] Nagao K, Inoue N, Wang YM, et al. Conjugated linoleic acid enhances plasma adiponectin level and alleviates hyperinsulinemia and hypertension in Zucker diabetic fatty (fa/fa) rats. Biochem Biophys Res Commun, 2003, Oct 17; 310(2): 562-6.
[31] Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 [J]. Nat Med, 2002, 8(7): 731-737.
[32] Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes; close associationwith insulin resistance and hyper-insulinemia [J]. J Clin Endocrinol Metab, 2001, 86(5): 1930-1935.
[33] Kadowaki T, Hara K, Yamauchi K, et al. Molecularmechanismof insulin resistance and obesity [J]. Exp Biol Med, 2003, 228(10): 1111-1117.
[34] Sethi JK, Vidal-PuigA. Visfatin: themissing link between intra-ab-dominal obesity and diabetes? [J]. Trends MolMed, 2005, 1(8): 344-347.
[35] Kralisch S, Klein J, LossnerU, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes [J]. J Endocrino, 2005, 185(3):R1-R8.
[36] Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fatdepot- specific mRNA expression in humans [J]. Diabetes, 2005, 54(10): 2911-2916.
[37] Haider DG, Schaller G, Kapiotis S, et al. The release of the adipocytokine visfatin is regulated by glucose and insulin [J]. Diabetologia, 2006, 49(8): 1909-1914.
[38] Frydelund-Larsen L, Akerstrom T, Nielsen S, et al. Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise [J]. Am J Physiol Endocrinol Metab, 2007, 292 (1): E24-E31.
[39] Hollander MH, Paarlberg KM, Huisjes AJ. Gestational diabetes: a review of the current literature and guidelines. Obstet Gynecol Surv. 2007 Feb; 62(2):125-36.
[40] Wijeyaratne CN, Ginige S, Arasalingam A, et al. Screening for gestational diabetes mellitus: the Sri Lankan experience. Ceylon Med J. 2006 Jun; 51(2): 53-8.
[41] Chan TF, Chen YL, Lee CH, et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig. 2006 Jul; 13(5): 364-7.
[42] Ranheim T, Haugen F, Staff A, et al, Adiponectin is reduced in gestational diabetes mellitus in normal weight women, Acta Obstet Gynecol Scand, 2004, 83(4): 341-347.
[43] Staiger K, Stefan N, Staiger H, et al. Adiponectin is functionally active in human isletsbut doesnot affect insulin secretory function orβ-cell lipoapoptosis [J]. J Clin Endocrinol Metab, 2005, 90(12): 6707-6713.
[44] Retnakaran R, Hanley AJ, Raif N, et al. Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications [J]. Diabetologia, 2005, 48(5): 993-1001.
[45] Furuta M, Tamai M, HanabusaT, et al. Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients [J]. Diabetes Res Clin Pract, 2006, 72(3): 302-307.
[46] Winzell MS, Nogueiras R, Dieguez C, et al. Dual action of adiponectin on insulin secretion in insulin-resistant mice [J]. Biochem Biophys Res Commun, 2004, 321(1): 154-160.
[47] Dudhbhai M, Lim L, Bombard A, et al. Characteristics of patients with abnormal glucose challenge test and normal oral glucose tolerance test results: comparison with normal and gestational diabetic patients. Am J Obstet Gynecol. 2006 May; 194(5): e42-5. Epub 2006 Apr 21.
[48] Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucoseutilization and fatty-acid oxidation by activating AMP-activated protein kinase [J]. Nat Med, 2002, 8(11): 1288-1295.
[49] Kharroubi I, Rasschaert J, Eizirik DL, et al. Expression of adiponectin receptors in pancreatic beta cells [J]. Biochem Biophys Res Commun, 2003, 312(4): 1118-1122.
[50] Xavier GS, Leclerc I, Salt IP, et al. Role of AMP-activated proten kinase in the regulation by glucose of islet beta cell gene expression [J]. Proc Natl Acad Sci USA, 2000, 97(8): 4023-4028.
[51] Huypens P, Moens K, Heimberg H, et al. Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells [J]. Life Sci, 2005, 77(11): 1273-1282.
[52] Schuit FC, Huypens P, HeimergH, et al. Glucose sensing in pancreaticβ-cells:a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus [J]. Diabetes, 2001, 50(1): 1-11.
[53] Shaibi GQ, Cruz ML, Weigensberg MJ, et al. Adiponectin Independently Predicts Metabolic Syndrome in Overweight Latino Youth. J Clin Endocrinol Metab, 2007, Feb 20; [Epub ahead of print].
[54] Hollander MH, Paarlberg KM, Huisjes AJ. Gestational diabetes: a review of the current literature and guidelines.Obstet Gynecol Surv. 2007 Feb; 62(2): 125-36.
[55] Wijeyaratne CN, Ginige S, Arasalingam A, et al. Screening for gestational diabetes mellitus: the Sri Lankan experience. Ceylon Med J. 2006 Jun; 51(2): 53-8.
[56] Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fatdepot- specific mRNA expression in humans [J]. Diabetes, 2005, 54(10): 2911-2916.
[57] Frydelund-Larsen L, Akerstrom T, Nielsen S, et al. Visfatin mRNAexpressionin human subcutaneous adipose tissue is regulated byexercise [J]. Am J Physiol Endocrinol Metab, 2007, 292 (1): E24-E31.
[58] Chan TF, Chen YL, Lee CH, et al. Decreased plasma visfatin concentrations in women with gestational diabetesmellitus [J]. J Soc Gynecol Investig, 2006, 13(5): 364-367.
[59] Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased visfatin concentrations in women with gestational diabetes mellitus [J]. Clin Sci (Lond), 2006, 110 (5): 605-609.
[60] Lewandowski KC, Stojanovic N, Press M, et al. Elevated serum levels ofvisfatin in gestationaldiabetes: a comparative study acrossvarious degrees ofglucose tolerance [J]. Diabetologia, 2007, 50(5): 1033-1037.
[61] Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine ofhuman fetalmembranes [J]. Am Jobstet Gyneco1, 2002, 187(4):1051-1058.
[62] Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation [J]. J Biol Chem, 2002, 277: 25863-25866.
[63] Matsuda M, Shimomural I, Sata M, et al. Role of adiponectin in preventing vascular stenosis: Themissing link of adipo-vascular axis [J]. J Biol Chem, 2002, 277: 37484-37491.
[64] Halaska MG, Vlk R, Feldmar P, et al. Predicting term birth weight using ultrasound and maternal characteristics. Eur J Obstet Gynecol Reprod Biol. 2006 Sep-Oct; 128(1-2): 231-5.
[2] Hollander MH, Paarlberg KM, Huisjes AJ. Gestational diabetes: a review of the current literature and guidelines. Obstet Gynecol Surv. 2007 Feb; 62(2): 125-36.
[3] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagonsis and classification of diabetes mellitus. Diabetes Care, 2003, 26 Suppl 1: S5-20.
[4] Wijeyaratne CN, Ginige S, Arasalingam A, et al. Screening for gestational diabetes mellitus: the Sri Lankan experience. Ceylon Med J. 2006 Jun; 51(2): 53-8.
[5] Kim C, Newton KM,Knopp RH.Gestational diabetes mellitus. Diabetesand incidence of type 2 diabetes: a systematic review.Diabetes Care, 2002, 25: 1862-1868.
[6] American Diabetes Association:Gestational diabetes mellitus.Diabetes Care, 2004, 27 Suppl 1: s88-90.
[7] Case J, Willoughby D, Haley-Zitlin V, et al. Preventing type 2 diabetes after gestational diabetes. Diabetes Educ. 2006 Nov-Dec; 32(6): 877-86.
[8] Kieffer EC, Tabaei BP, Carman WJ, et al. The influence of maternal weight and glucose tolerance on infant birthweight in Latino mother-infant pairs. Am J Public Health. 2006 Dec; 96(12): 2201-2208.
[9] Freire CM, Nunes Mdo C, Barbosa MM, et al. Gestational diabetes: a condition of early diastolic abnormalities in young women. J Am Soc Echocardiogr. 2006 Oct; 19(10): 1251-6.
[10] Shuldiner AR,Yang R,Gong DW. Resistin, obesity and insulin resistance-theemerging role of the adipocyte as an endocrine or gan. N Engl J Med, 2001, 345(18): 1345.
[11] Hotamisligil GS, Shargill NS,Spiegelman BM, et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.Science. 1993 Jan 1; 259(5091): 87-91.
[12] Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased visfatin concentrations in women with gestational diabetes mellitus [J].Clin Sci (Lond), 2006, 110(5): 605-609.
[13] Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001 Aug; 7(8): 941-6.
[14] Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001 Aug; 7(8): 947-53.
[15] Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun; 89(6): 2548-56.
[16] Kadowaki T, Yamauchi T. Adiponectin and adiponectin eceptors. Endocr Rev. 2005 May; 26(3): 439-51.
[17] Kadowaki T, Hara K, Yamauchi K, et al. Molecularmechanismof insulin resistance and obesity [J]. Exp Biol Med, 2003, 228(10): 1111-1117.
[18] Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat thatmimics the effects of insulin [J]. Science, 2005, 307(5708): 426-430.
[19] American Diabetes Assccietion. Gestational diabetes mellitus. Diabetes care, 2002; 25: s94-96.
[20] American Diabetes Association:Gestational diabetes mellitus. Diabetes Care, 2004, 27 Suppl 1: s88-90.
[21] Boland E, Monsod T, Delucia M, et al. Limitations of conventional methodsof self-monitoring of blood glucose: lessons learned from 3 day of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care, 2001, 24: 1858-1862.
[22] Yamashita H, Jianhua S, Friedman JE. Physiologic and moleculae altera tions incarbohydrate metabolism during pregnancy and gestational. Diabetes Mellitus. J. Clin. Obst. Gyn. 2000, 43: 87-98.
[23] Okereke NC, Huston-Presley L, Amini SB,Kalhan S, Catalano PM.Longitudinal changes in energy expenditure and body composition in obese women with nomal and impaired glucose tolerance. Am J Physiol Endocrinol Metad. 2004; 287(3): E472-279.
[24] Connolly CC, Aglione, Smith MS, Lacy DB, Moore MC.Insulin action during late pregnancy in the conscious dog? Am J Physiol Endocrinol Metad. 2004; 286(6): E909-915.
[25] Mulford MI, Jovanonic-peterson CM. Alternative therapies for the management of gestational diabetes. Clin Perintol, 1993; 20: 619-634.
[26] Fadl H, Ostlund I, Nilsson K, et al. Fasting capillary glucose as a screening test for gestational diabetes mellitus. BJOG. 2006 Sep; 113(9): 1067-71.
[27] Akbay E, Tira MB, Yetkin, et al. Insulin secretion and insulin sensitivity in normal pregnancy and gestational diabetes mellitus. Gynecol Endocrinol, 2003, 17: 137-142.
[28] Smirnakis KV, Martinez A, Blatman KH, et al. Early pregnancy insulin resistance and subsequent gestational dibetes mellitus. Diabetes Care, 2005, 28: 1207-1208.
[29] Buchanan TA, Xiang A, Kjos SL, et al. Gestational diabetes:antepartum characteristics that predict postpartum glucose intolerance and type 2 diabetes in Latino women. Diabetes, 1998, 47: 1302-1310.
[30] Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational diabetes mellitusand its association with Type 2 diabetes. Diabet Med, 2004, 21(2): 103-113.
[31] Maeda K, Okubo K, Shimomura I, et al. c-DNA cloning and expression of a noveladipose specific collagen-like factor, apMI (Adipose Most abundant Gene transcript1). Biochem Biophys Res Commun, 1996. 221: 286-289.
[32] Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 2001, 7: 941-946.
[33] Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substance. Ann N Y Acad Sci, 1999, 892: 146-154.
[34] Yokota T, Oritani K, Takahashi I, et al, Adiponectin, a new member of the family of soluble defense collages, negatively regulates the growth of mywlomonocytic progenitors and the functions of macrophages. Blood, 2000, 96: 1723-1732.
[35] Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 1999, 100: 2473-2476.
[36] Ranheim T, Haugen F, Staff A, et al, Adiponectin is reduced in gestational diabetes mellitus in normal weight women, Acta Obstet Gynecol Scand, 2004, 83(4): 341-347.
[37] Ranheim T, Haugen F, Staff AC, et al. Adiponectin is reduced in gestational diabetes mellitus in normal weight woman. Acta Obstet Gynecol Scand, 2004, 83(4): 341-347.
[38] Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased visfatin concentrations in women with gestational diabetes mellitus [J]. Clin Sci (Lond), 2006, 110(5): 605-609.
[39]陈蕾,项坤三,贾伟平等.血清脂联素浓度与体脂分布及葡萄糖钳夹试验中胰岛素敏感性的关系.中华医学杂志. 2005, 85(21): 1456-1459.
[40] Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fatdepot- specificm RNA expression in humans [J]. Diabetes, 2005, 54(10): 2911-2916.
[41] Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 [J]. Nat Med, 2002, 8(7): 731-737.
[42] Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes; close associationwith insulin resistance and hyperinsulinemia [J]. J Clin Endocrinol Metab, 2001, 86(5): 1930-1935.
[43] Winzell MS, Nogueiras R, Dieguez C, et al. Dual action of adiponectin on insulin secretion in insulin-resistant mice [J]. Biochem Biophys Res Commun,2004, 321(1): 154-160.
[44] Furuta M, Tamai M, HanabusaT, et al. Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients [J]. Diabetes Res Clin Pract, 2006, 72(3): 302-307.
[45] Sethi JK,Vidal-PuigA.Visfatin: themissing link between intra-abdominal obesity and diabetes? [J]. Trends MolMed, 2005, 11(8): 344-347.
[46] Kralisch S, Klein J, LossnerU, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes [J]. J Endocrino, l, 2005, 185(3): R1-R8.
[47] Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fatdepot- specificm RNA expression in humans [J]. Diabetes, 2005, 54(10): 2911-2916.
[48] Haider DG, Schaller G, Kapiotis S, et al. The release of the adipocytokine visfatin is regulated by glucose and insulin [J]. Diabetologia, 2006, 49(8): 1909-1914.
[49] Filippatos TD, Derdemezis CS, Kiortsis DN, et al. Increased plasma levelsof visfatin/ pre-B cell colony-enhancing factor in obese and over weight patients with metabolic syndrome [J]. J Endocrinol Invest, 2007, 30(4): 323-326.
[50]刘蓉,朱剑,王茜,等.不同糖耐量人群及糖尿病患者血浆内脂素与血糖及胰岛功能的关系研究[J].中国实用内科杂志, 2007, 27(16): 1278-1281.
[1] Kim C, Newton KM, Knopp RH. Gestational diabetes mellitus. Diabetesand incidence of type 2 diabetes: a systematic review. Diabetes Care, 2002, 25: 1862-1868.
[2] American Diabetes Association: Gestational diabetes mellitus.Diabetes Care, 2004, 27 Suppl 1: s88-90.
[3] Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat thatmimics the effects of insulin [J]. Science, 2005, 307(5708): 426-430.
[4] Shuldiner AR,Yang R, Gong DW. Resistin, obesity and insulin resistance-the emerging role of the adipocyte as an endocrine organ.N Engl J Med, 2001, 345(18):1345-6.
[5] Hotamisligil GS, Shargill NS, Spiegelman BM, et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 1993, 259 (5091): 87-91.
[6] Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature, 1994, 372(6505): 425-32.
[7] Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature, 2001, 18; 409 (6818): 307-12.
[8] Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.Nature, 2005, Jul 21; 436 (7049): 356-62.
[9] Shulman GI. Cellular mechanisms of insulin resistance.J Clin Invest, 2000 Jul; 106(2): 171-6.
[10] Friedman JM. Obesity in the new millennium. Nature, 2000 Apr 6; 404(6778): 632-4.
[11] Hotamisligil GS.The role of TNF alpha and TNF receptors in obesity and insulin resistance. J Intern Med,1999, Jun; 245(6): 621-5.
[12] Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol, 2006, Oct; 6(10): 772-83.
[13] Moschos S, Chan J L, Mantzoros C S. Leptin and reproduction: a review. Fertil Steril, 2002; 77( 3): 433-444.
[14] Straczkowski M, Kowalska I, Dzienis-Straczkowska S, et al. Changes in tumor necrosis factor-αsystem and insulin sensitivity during an exercise training program in obese woman with normal and impaired goucose tolerance. Eur J Endocrinol, 2001, 45(3): 273-280.
[15] Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem, 1995, Nov 10; 270(45): 26746-9.
[16] Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem,1996, May 3; 271(18): 10697-703.
[17] Maeda K, Okubo K, Shimomura I, et al. c-DNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun, 1996, Apr 16; 221(2): 286-9.
[18] Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo), 1996, Oct; 120(4): 803-12.
[19] Crouch E, Persson A, Chang D, et al. Molecular structure of pulmonary surfactant protein D (SP-D). J Biol Chem, 1994, Jun 24; 269 (25): 17311-9.
[20] McCormack FX, Pattanajitvilai S, Stewart J, et al. The Cys6 intermolecular disulfide bond and the collagen-like region of rat SP-A play critical roles in interactions with alveolar type II cells and surfactant lipids. J Biol Chem, 1997, Oct 31; 272(44): 27971-9.
[21] Wong GW, Wang J, Hug C, et al. A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci U S A, 2004, Jul 13; 101(28): 10302-7.
[22] Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens,negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 2000, Sep 1; 96(5):1723-32.
[23] Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol, 1998, Mar 12; 8(6): 335-8.
[24] Schaffler A, Barth N, Palitzsch KD, et al. Mutation analysis of the human adipocyte- specific apM-1 gene. Eur J Clin Invest, 2000, Oct; 30(10): 879-87.
[25] Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord, 2000, Jul; 24(7): 861-8
[26] Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes, 2002, Sep; 51(9): 2734-41.
[27] Xu A, Chan KW, Hoo RL, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem, 2005, May 6; 280(18): 18073-80.
[28] Nagasawa A, Fukui K, Funahashi T, et al. Effects of soy protein diet on the expression of adipose genes and plasma adiponectin. Horm Metab Res, 2002, Nov-Dec; 34(11-12): 635-9.
[29] Flachs P, Mohamed-Ali V, Horakova O, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia, 2006 Feb; 49(2): 394-7.
[30] Nagao K, Inoue N, Wang YM, et al. Conjugated linoleic acid enhances plasma adiponectin level and alleviates hyperinsulinemia and hypertension in Zucker diabetic fatty (fa/fa) rats. Biochem Biophys Res Commun, 2003, Oct 17; 310(2): 562-6.
[31] Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 [J]. Nat Med, 2002, 8(7): 731-737.
[32] Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes; close associationwith insulin resistance and hyper-insulinemia [J]. J Clin Endocrinol Metab, 2001, 86(5): 1930-1935.
[33] Kadowaki T, Hara K, Yamauchi K, et al. Molecularmechanismof insulin resistance and obesity [J]. Exp Biol Med, 2003, 228(10): 1111-1117.
[34] Sethi JK, Vidal-PuigA. Visfatin: themissing link between intra-ab-dominal obesity and diabetes? [J]. Trends MolMed, 2005, 1(8): 344-347.
[35] Kralisch S, Klein J, LossnerU, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes [J]. J Endocrino, 2005, 185(3):R1-R8.
[36] Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fatdepot- specific mRNA expression in humans [J]. Diabetes, 2005, 54(10): 2911-2916.
[37] Haider DG, Schaller G, Kapiotis S, et al. The release of the adipocytokine visfatin is regulated by glucose and insulin [J]. Diabetologia, 2006, 49(8): 1909-1914.
[38] Frydelund-Larsen L, Akerstrom T, Nielsen S, et al. Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise [J]. Am J Physiol Endocrinol Metab, 2007, 292 (1): E24-E31.
[39] Hollander MH, Paarlberg KM, Huisjes AJ. Gestational diabetes: a review of the current literature and guidelines. Obstet Gynecol Surv. 2007 Feb; 62(2):125-36.
[40] Wijeyaratne CN, Ginige S, Arasalingam A, et al. Screening for gestational diabetes mellitus: the Sri Lankan experience. Ceylon Med J. 2006 Jun; 51(2): 53-8.
[41] Chan TF, Chen YL, Lee CH, et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig. 2006 Jul; 13(5): 364-7.
[42] Ranheim T, Haugen F, Staff A, et al, Adiponectin is reduced in gestational diabetes mellitus in normal weight women, Acta Obstet Gynecol Scand, 2004, 83(4): 341-347.
[43] Staiger K, Stefan N, Staiger H, et al. Adiponectin is functionally active in human isletsbut doesnot affect insulin secretory function orβ-cell lipoapoptosis [J]. J Clin Endocrinol Metab, 2005, 90(12): 6707-6713.
[44] Retnakaran R, Hanley AJ, Raif N, et al. Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications [J]. Diabetologia, 2005, 48(5): 993-1001.
[45] Furuta M, Tamai M, HanabusaT, et al. Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients [J]. Diabetes Res Clin Pract, 2006, 72(3): 302-307.
[46] Winzell MS, Nogueiras R, Dieguez C, et al. Dual action of adiponectin on insulin secretion in insulin-resistant mice [J]. Biochem Biophys Res Commun, 2004, 321(1): 154-160.
[47] Dudhbhai M, Lim L, Bombard A, et al. Characteristics of patients with abnormal glucose challenge test and normal oral glucose tolerance test results: comparison with normal and gestational diabetic patients. Am J Obstet Gynecol. 2006 May; 194(5): e42-5. Epub 2006 Apr 21.
[48] Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucoseutilization and fatty-acid oxidation by activating AMP-activated protein kinase [J]. Nat Med, 2002, 8(11): 1288-1295.
[49] Kharroubi I, Rasschaert J, Eizirik DL, et al. Expression of adiponectin receptors in pancreatic beta cells [J]. Biochem Biophys Res Commun, 2003, 312(4): 1118-1122.
[50] Xavier GS, Leclerc I, Salt IP, et al. Role of AMP-activated proten kinase in the regulation by glucose of islet beta cell gene expression [J]. Proc Natl Acad Sci USA, 2000, 97(8): 4023-4028.
[51] Huypens P, Moens K, Heimberg H, et al. Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells [J]. Life Sci, 2005, 77(11): 1273-1282.
[52] Schuit FC, Huypens P, HeimergH, et al. Glucose sensing in pancreaticβ-cells:a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus [J]. Diabetes, 2001, 50(1): 1-11.
[53] Shaibi GQ, Cruz ML, Weigensberg MJ, et al. Adiponectin Independently Predicts Metabolic Syndrome in Overweight Latino Youth. J Clin Endocrinol Metab, 2007, Feb 20; [Epub ahead of print].
[54] Hollander MH, Paarlberg KM, Huisjes AJ. Gestational diabetes: a review of the current literature and guidelines.Obstet Gynecol Surv. 2007 Feb; 62(2): 125-36.
[55] Wijeyaratne CN, Ginige S, Arasalingam A, et al. Screening for gestational diabetes mellitus: the Sri Lankan experience. Ceylon Med J. 2006 Jun; 51(2): 53-8.
[56] Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fatdepot- specific mRNA expression in humans [J]. Diabetes, 2005, 54(10): 2911-2916.
[57] Frydelund-Larsen L, Akerstrom T, Nielsen S, et al. Visfatin mRNAexpressionin human subcutaneous adipose tissue is regulated byexercise [J]. Am J Physiol Endocrinol Metab, 2007, 292 (1): E24-E31.
[58] Chan TF, Chen YL, Lee CH, et al. Decreased plasma visfatin concentrations in women with gestational diabetesmellitus [J]. J Soc Gynecol Investig, 2006, 13(5): 364-367.
[59] Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased visfatin concentrations in women with gestational diabetes mellitus [J]. Clin Sci (Lond), 2006, 110 (5): 605-609.
[60] Lewandowski KC, Stojanovic N, Press M, et al. Elevated serum levels ofvisfatin in gestationaldiabetes: a comparative study acrossvarious degrees ofglucose tolerance [J]. Diabetologia, 2007, 50(5): 1033-1037.
[61] Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine ofhuman fetalmembranes [J]. Am Jobstet Gyneco1, 2002, 187(4):1051-1058.
[62] Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation [J]. J Biol Chem, 2002, 277: 25863-25866.
[63] Matsuda M, Shimomural I, Sata M, et al. Role of adiponectin in preventing vascular stenosis: Themissing link of adipo-vascular axis [J]. J Biol Chem, 2002, 277: 37484-37491.
[64] Halaska MG, Vlk R, Feldmar P, et al. Predicting term birth weight using ultrasound and maternal characteristics. Eur J Obstet Gynecol Reprod Biol. 2006 Sep-Oct; 128(1-2): 231-5.